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Abstract
The Animal Research: Reporting of In Vivo Experiments (ARRIVE) guidelines were devel-
oped to address the lack of reproducibility in biomedical animal studies and improve the
communication of research findings. While intended to guide the preparation of peer-re-
viewed manuscripts, the principles of transparent reporting are also fundamental for in vivo
databases. Here, we describe the benefits and challenges of applying the guidelines for the
International Mouse Phenotyping Consortium (IMPC), whose goal is to produce and pheno-
type 20,000 knockout mouse strains in a reproducible manner across ten research centres.
In addition to ensuring the transparency and reproducibility of the IMPC, the solutions to the
challenges of applying the ARRIVE guidelines in the context of IMPC will provide a resource
to help guide similar initiatives in the future.
PLOS Biology | DOI:10.1371/journal.pbio.1002151 May 20, 2015 1 / 11
OPEN ACCESS
Citation: Karp NA, Meehan TF, Morgan H, Mason
JC, Blake A, Kurbatova N, et al. (2015) Applying the
ARRIVE Guidelines to an In Vivo Database. PLoS
Biol 13(5): e1002151. doi:10.1371/journal.
pbio.1002151
Published: May 20, 2015
Copyright: © 2015 Karp et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any
medium, provided the original author and source are
credited.
Data Availability Statement: All of the IMPC data
are available through both the web portal by a
spreadsheet download from each graph or via
programmatic access (see https://www.
mousephenotype.org/data/documentation/api-help).
Funding: A number of grants from the National
Institutes of Health supported the work. In particular
SDMB, AMM, SW, HM, AB, TFM, JCM, HP, NK, DS,
JJ, NAK, VI, PM, JKW, and DGM were supported by
grant U54 HG006370-01; CLR by U42-OD11174 and
U54-HG006348; KLS and EJC by U54-HG006332;
AMF, KCKL, and DBW by U54 HG006364-01; KCKL
by U42 OD011175 and RP by U54-HG006348.
SDMB, AMM, SW, HM, and AB were also supported
by the European Commission—FP6 [LSHG-CT-
2006-037811]. AMF was supported by Genome
Canada (grant LSARP OGI-051). RFM was
supported by the Wellcome Trust (grants: 083573/Z/
07/Z, and 090532/Z/09/Z). MHdA was supported by
Introduction
In 2010, the Animal Research: Reporting of In Vivo Experiments (ARRIVE) guidelines were
published [1] to address the growing concerns with poor experimental design and lack of trans-
parent reporting of in vivo experiments in the published literature [2–4]. The guidelines consist
of a checklist of 20 items, which are considered key to describing a study comprehensively and
transparently (Fig 1). Transparent reporting is a fundamental component required to ensure
reproducibility of animal research and allow later inclusion in meta-analytic studies [5]. To our
knowledge, no specific guidelines exist for an in vivo database, and there has been no report of
the use of the ARRIVE guidelines to inform the collection, analysis, and presentation of data in
a pre-publication database. Yet the transparency needed is equally essential in this situation.
The International Mouse Phenotyping Consortium (IMPC) [6] aims to phenotype knock-
outs for all protein coding genes in the mouse genome and hence provide an invaluable re-
source to the community, given that the mouse is the premier model organism for
understanding gene function in development and disease. The IMPC community has defined a
core set of procedures to assess multiple biological systems and has developed a central re-
source (www.mousephenotype.org) to disseminate the data. The database contains continuous,
categorical, count, and image data for over 734,284 experiments on 46,972 mice as of January
2015.
Here, we describe how the IMPC applied the ARRIVE guidelines to a large data resource
and highlight the challenges and how we addressed them. Applying the ARRIVE guidelines
has required extensive development, which has not been confined to the database and web por-
tal but has also impacted on communication and understanding within the community.
Achieving transparency is not a simple task but has benefits not only to the consumers of the
data but also the experimenters and is critical for the value of the research to be fully realised.
The Aims and Challenges of Setting Up a Large-Scale Database
A large-scale database aims to consolidate information into one site for maximum exposure
and to add functionality to mine and explore data. The scale of the project, with many types of
variables and data from many sources, brings many challenges in capturing the data (defining
what to capture and methods of capture), data organisation, and data presentation. A signifi-
cant challenge for a database portal is how to organise the information in a logical way that
leads to readable pages that do not overwhelm a user upon first inspection. The ARRIVE guide-
lines were developed specifically for peer-reviewed scientific publications of in vivo data, but
the goals of transparency are equally applicable to databases and critical to allow reproducible
research. We therefore decided to use the ARRIVE guidelines to review and subsequently refine
our approach to maximise the value of the data we were presenting.
Application of the ARRIVE Guidelines
ARRIVE Guidelines—Introduction—Background and Objective (Items 3
and 4)
The IMPC home page, http://www.mousephenotype.org/goals-and-background, details the
goals of the project and the relevance to human biology.
ARRIVE Guidelines—Methods—Ethical Statement (Item 5) and
Funding Information (Item 20)
IMPC includes ten institutes collecting phenotyping data, guided by their own ethical review
panels, licenses, and accrediting bodies that reflect the national and/or geo-political constructs
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in which they operate. The ethical and funding information were not initially captured, but our
review steered by the guidelines drove us to develop an ethical and funding survey. The survey
provides a transparent view and enables prospective users of the data to understand the ethical
framework in which the data were collected.
ARRIVE Guidelines—Methods—Experimental Procedures (Item 7) and
Experimental Outcomes (Item 12)
The experimental procedures in IMPC are defined by standardised data format in the Interna-
tional Mouse Phenotyping Resource of Standardised Screens (IMPReSS) database (https://
www.mousephenotype.org/impress/). IMPReSS is based on a pipeline concept, which is a series
of experimental procedures performed in a specified order. Each procedure defines the pur-
pose, experimental design, the protocol, the measured variables, potential QC failure criteria,
methodology, variables measured, and the metadata to be captured. The information is orga-
nised such that each data point can be associated with the relevant procedural and mouse
information.
To provide traceability, IMPReSS also stores a record of change histories. IMPReSS thus
provides the framework not only for transparency in the procedure and what data are required
to be captured but also stores information to facilitate subsequent analysis, hence making it the
backbone of the database and web portal. The development of this resource has required exten-
sive collaboration with the institutes, area experts, and database engineers.
Fig 1. A summary of the areas encompassed by the ARRIVE guidelines. The ARRIVE guidelines are organised into twenty sections, which cover all
areas of a typical research manuscript. Image credit: NC3Rs: https://www.nc3rs.org.uk/arrive-guidelines.
doi:10.1371/journal.pbio.1002151.g001
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ARRIVE Guidelines—Methods—Experimental Animals (Item 8)
The scale of the project necessitated the development of an International MicroInjection
Tracking System (iMITS), which is the repository of the genotypes and coordinates production
and phenotyping. The scale has also required an automated method of data capture from phe-
notyping centres. It is supported by a strict data standard that defines, in addition to the vari-
ables defined in the procedures at IMPReSS, data about each animal (Local ID, date of birth,
strain, sex, and centre).
ARRIVE Guidelines—Methods—Housing and Husbandry (Item 9) and
Results—Adverse Events (Item 17)
To capture housing and husbandry information, the community came together and, based on
the ARRIVE guidelines, the Gold Standard Publication Checklist reporting guidelines [7], and
the Genetically Altered (GA) Passport [8], constructed a series of questions and answers that
was used to develop a housing and husbandry survey. The phenotyping pipelines have been de-
signed to ensure that there are no welfare-related issues for a normal mouse; however, inciden-
tal welfare issues may arise from the environment and the genetic background of the mice.
Animals presenting with these incidental welfare issues will be assessed on a case-by-case basis
to determine if the issue can be managed through remedial care, such as wet mash on the cage
floor for runting or clipping teeth in the case of malocclusions, or whether our ethical obliga-
tion to the animals and the scientific endpoints are better served by euthanizing the affected an-
imal and providing a replacement. In addition to these incidental welfare concerns, a welfare
issue could occur as a consequence of the genetic alteration carried by the mice. Two comple-
mentary approaches are used to identify and manage these welfare issues. First, during the gen-
eration of the first homozygous progeny, we assess basic dysmorphology. If significant welfare
concerns are raised, then the breeding strategy is modified to discontinue the generation of ho-
mozygous mice and heterozygous mice are phenotyped instead. In addition to this early assess-
ment, ongoing monitoring is carried out through the lifetime of the colony. When animals do
present a welfare concern, either an intervention is made in the form of the Alternate Mouse
Pipeline or, when applicable, remedial action is taken within husbandry (e.g., long water spouts
or food on cage base) or within experimental procedures (e.g., an alternate anesthetic is used or
selected tests are omitted). The Alternate Mouse Pipeline is a bespoke phenotyping pipeline in
which the age and procedures are adapted to manage the welfare of the line. Currently the
community is in the process of defining the Alternate Mouse Pipeline within IMPReSS that
will, in the future, allow this data to be captured and disseminated. These two complementary
approaches allow us to maximise the value of information extracted from the lines while mini-
mising welfare issues. If mice or cryopreserved sperm are requested, any welfare concerns are
provided in a GA passport [8].
ARRIVE Guidelines—Methods—Study Design (Item 6) and Allocating
Animals to Experimental Groups (Item 11)
As a high-throughput project, the community is following a general design of testing seven ani-
mals per sex for each knockout strain to be compared to the control data. Within the analysis
we consider the mouse as the experimental unit. Since we cannot randomly allocate animals to
experimental groups, we rely on Mendelian inheritance to provide the randomisation method.
However, there are still many other aspects of the experiment where planning is necessary to
avoid bias (e.g., order effects). Whilst the general approach and procedures are captured and
tightly defined in IMPReSS, implementation (e.g., blinding) could vary significantly between
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institutes. Discussions on study design and implementation identified terminology and usage
differences as a significant impediment to communication within the consortium. We there-
fore developed a standardised language to describe various aspects of the experimental design.
The resulting Mouse Experimental Design Ontology (MEDO) is hosted at the BioPortal for
biomedical ontologies (http://bioportal.bioontology.org/ontologies/MEDO) For example, the
phrase “control mouse” in the context of a gene knockout was initially thought to have no am-
biguity. In fact, there were four different possible control designs that could be implemented
(Table 1). A similar issue affects potential confounders since a strategy followed by one insti-
tute might not be feasible in another. Examples of differences occurred in the management of
instrumentation bias (S1 Table) or in blinding strategies used (Table 2). As a community, we
termed this study design information the “workflow.” The workflow data are recorded annually
via a survey using the MEDO ontology. The practical reality of experimental design is that
there is no perfect solution; therefore, transparency is needed to capture how experiments were
implemented to allow users to independently assess the potential strengths and weaknesses in
the design. This level of transparency also encourages good practice within the consortium. For
example, the Japan Mouse Clinic switched from an “alternate mouse”method to a “cage active
randomisation method” to minimise potential order effects when assaying mice.
The standardised language developed is specific to the variation in implementation that
could occur within our community, but also to variation sources that were felt to have the po-
tential to have a biological impact on the experimental outcome that were not controlled by
standardisation within our studies. As a result, the language we developed is not generic but
could form a starting point for other communities.
ARRIVE Guidelines—Methods—Sample Size (Item 10)
As a high-throughput project, the target sample size of 14 animals (seven per sex) per knockout
strain is relatively low. This number was arrived at after a community-wide debate to find the
lowest sample size that would consume the least amount of resources while achieving the goal
of detecting phenotypic abnormalities. At times, viability issues or the difficulty in administer-
ing a test might further limit the number of animals. As such, whenever data are visualised, the
number of animals phenotyped is listed.
Table 1. The various control design options available and associated definitions.
Control design option Deﬁnition
Line mate control The process of using control WT mice that are generated from a breeding
programme of HET*HET or HET*WT crosses used to generate the mutant of
interest.
Littermate control The process of using WT mice that are true siblings and hence were generated
from a HET*HET, or a HET*WT cross that generated the mutant of interest. If
HET mice are the controls, the control mice are true siblings from a HOM*HET
or a HET*HET cross that generated the mutant of interest.
Pooled genetic
control
The process of using WT mice from HET*HET or HET*WT breeding that
generates mutant mice. This can be from matings that generate a variety of KO
alleles, all of which are on the same genetic background.
Production colony
control
A process in which WT mice from a breeding colony of the same genetic
background are used.
The table lists the various ontologies and associated deﬁnitions that were developed to describe the control
strategies used in the implementation of the phenotyping experiments. WT indicates wild type, KO
indicates knockout, HOM indicates homozygous, and HET indicates heterozygous.
doi:10.1371/journal.pbio.1002151.t001
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In a high-throughput environment, replication of individual lines is not cost effective. In-
stead, we are generating and characterising a common set of six “reference” knockout lines that
will present a wide range of phenotypes based on previously published research.
ARRIVE Guidelines—Methods—Statistical Methods (Item 13)
Ensuring that the appropriate statistical analysis is applied is a common problem in biology
[9]. For high-throughput phenotyping platforms, this is an area of active research [10,11]. De-
veloping an analysis pipeline for a resource with data from many sources is challenged by the
number of variables, different data types, the data quantity for an institute, and variation in ex-
perimental workflow. One example of variation in workflow is in the difference between data
from the Institut Clinique de la Souris, which is collected with a design of one batch of knock-
out mice with concurrent controls, and that of the Wellcome Trust Sanger Institute, in which
the knockout and control mice are collected in multiple batches and not necessarily on the
same day. The analysis is further complicated by the requirement that it be completely unsu-
pervised, with no user intervention. As such, an analysis pipeline has to be robust, it must pro-
cess the data consistently, and it cannot be fine-tuned for all possible scenarios.
To address the analysis questions, the international community has come together to form
an IMPC Statistical Technical Group to systematically address these issues and inform the re-
search that is needed in this area. Consequently, we have implemented an analysis pipeline that
applies the best statistical tests based on the assay and the structure of the data (e.g., control
method used). To ensure this analysis is transparent, we have developed a package of tools
called PhenStat that uses the popular statistical language R. The package is freely available
from Bioconductor (http://www.bioconductor.org/packages/release/bioc/html/PhenStat.html),
and the application is version-controlled, as there is still active research ongoing in this area of
data analysis. We also provide an explanation of the analysis, which can be accessed from the
IMPC ARRIVE landing page.
On the web portal, each graphical representation includes a statistical summary with p-val-
ues and effect sizes, with the ability for users to obtain more information about the statistical
method implemented (S1 Fig). As data can be analysed in many ways, and each way has
strengths and weaknesses, we have developed tools and procedures to enable users to obtain
raw data for independent analysis, either via spreadsheet downloads, file transfer protocol (ftp)
access, or automatic programmatic interfaces.
Table 2. Potential blinding strategies and associated definitions used to describe the experiments.
Blinding strategy Deﬁnition
Blinded A process in which the person performing the phenotyping does not have access to
either genotype or allele information.
Unblinded A process in which the experiment is run with no blinding, i.e., both genotype and
allele are visible to the person performing the phenotyping procedure.
Genotype free
blinding
A process in which the person performing the procedure has access to the allele,
but not the genotype information.
Allele free blinding A process in which the person performing the procedure knows the genotype
information but not the allele information of the subject being phenotyped
The table lists the various ontologies and associated deﬁnitions that were developed to describe the
blinding strategies implemented in phenotyping experiments.
doi:10.1371/journal.pbio.1002151.t002
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ARRIVE Guidelines—Results—Numbers, Baseline Data, and
Outcomes and Estimation (Items 14–16)
The challenge with the analysis is not only in selecting the most appropriate analysis platform
but in presenting all the results and the concomitant information in a user-accessible way. Ac-
companying the graphical descriptions of the data are summary measures for each group
of mice.
Data are rarely excluded from the analysis. Exclusion can arise from two mechanisms. First-
ly, data points may fail quality control (QC) during data collection. An explanation is provided
using a standardised set of options as agreed by area experts. An example is the explanation
“Procedure Failed—Insufficient Sample—Blood sample.” Secondly, data are QC’d after upload
from the institute to the database, where data of concern are investigated using Phenodcc, a set
of tools that visualise the data and track concerns. This approach is essential when dealing
which large volumes of data. Data are only QC-failed if clear technical reasons can be found for




Results are interpreted automatically following statistical analysis by the assignment of a Mam-
malian Phenotype Ontology term (MP term) when a significance threshold (p< 0.0001),
agreed upon by the community, is reached. The Mammalian Phenotype Ontology is a stan-
dardised ontology developed by the Mouse Genome Informatics group for describing a pheno-
type. The use of the standardised ontology is critical to allow comparison across studies and
species.
The ARRIVE guidelines invite comments on the study limitations, including any potential
sources of bias and imprecision (Item 18b). This is an area of active discussion amongst the
IMPC Statistical Technical Group. For example, the group is considering methodologies to es-
timate the false discovery rate.
ARRIVE Guidelines—Discussion—Generalizability/Translation (Item
19)
Mouse repositories play an important role in the generalizability of results by allowing re-
searchers to perform follow-up studies on genetically identical animals to those used in previ-
ous analysis. All strains generated by the IMPC are available to the research community via the
established mouse repositories (e.g., Knockout Mouse Repository). These repositories include
details about allele structure, genetic background, pathogen exclusion list and any potential is-
sues in husbandry and welfare that may result from carried mutations. This information in-
creases the likelihood of reproducing previous results, which is important for translating
mouse research to humans [5].
Many animal experiments study only one sex, typically the males, to avoid potential issues
with oestrogen cycles. There has been growing concern over the sex imbalance in biomedical
research [12–14] and this had led to the United States National Institutes of Health now requir-
ing all grant applicants to consider both sexes in preclinical studies [15]. Fortunately, IMPC de-
cided at the start of the project that phenotype data should be collected from both sexes, and
this design supports the generalizability of any findings. In addition, our continuous analysis
pipeline is designed to detect sexual dimorphism and we associated a tag to the MP terms to
classify the effect observed (S2 Fig).
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Mouse knockout (or null) mutations lead to the absence of the gene product and are recog-
nized as a standard approach in all model organisms for assessing gene function. However, not
all aspects of gene function will be revealed by the generation of a knockout mutation. For ex-
ample, gain of function effects that might arise from the introduction of a specific amino acid
change in a protein would not be uncovered. Nevertheless, many Mendelian disorders in the
human population, including rare diseases, will be caused by severe loss of function effects for
which the data generated from mouse knockout mutations will be highly informative. More-
over, recent studies [16] have found a large number of associations between the phenotypes of
Mendelian and complex diseases that link complex disorders to a unique spectrum or “code”
of Mendelian loci. In addition, common variants associated with complex disease are enriched
in those Mendelian loci. This underscores the wider utility of examining loss-of-function alleles
in the mouse. As a translational resource, we have developed an automated analysis pipeline to
detect phenotypic similarities between inherited human diseases and our knockout mouse
lines. This pipeline uses a semantic matching algorithm termed PhenoDigm to detect and
score similarities between human clinical observations and mouse phenotypes [17]. We present
the links between human disease and IMPC lines on our website, along with the underlying ev-
idence. Lines with interesting disease relationships can then be ordered for further research
into the pathobiology of the disease and drug target validation.
Conclusions
Applying the ARRIVE guidelines for a phenotype resource generated by an international com-
munity introduced many challenges, some specific to a data resource and others that are more
general.
The first set of challenges arose in applying guidelines intended for a scientific publication
to a data resource. The detail needed to meet the guidelines required significant organisation
and informatics infrastructure to enable the capture, QC, analysis, and storage of the raw and
derived information. To do this, the IMPC developed several resources: the IMPReSS database,
which standardizes procedures and captures information needed to reproduce experiments;
the PhenStat analysis package, which defines the statistical procedures to enable others to repli-
cate analysis; iMITS, which tracks mouse production and phenotyping milestones; and finally,
Phenodcc, which supports QC of the data. We have also developed tools to support data down-
load to allow data to be analysed independently. Another issue specific to data resources is the
presentation of the large volume of data necessary to be transparent. Through a user-driven de-
sign approach, we developed a web portal that gives an overview of gene-phenotype associa-
tions with the ability to drill down to details that include graphs, statistical analysis results, and
numbers of animals involved. We have also constructed an ARRIVE page (https://www.
mousephenotype.org/about-impc/arrive-guidelines) that consolidates all the information.
These efforts have provided the transparency that is essential to allow reflective assessment of
our data.
A second, more general set of issues reflects a lack of standards in how experiments are de-
scribed. This necessitated the development of a standardised language with defined terms and
definitions, coupled with the use of surveys to clarify each centres’ implementation strategy.
Our experiences are likely to reflect a general issue in the biological community and could help
explain the lack of progress in applying the ARRIVE guidelines [9]. As a first step, we needed
to give priority to detailed explanation of experimental implementation. The development of a
standardised language has allowed us to capture and provide transparency in the experimental
design, which also encourages best practice.
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The ARRIVE guidelines have provided a framework to consider our ethical responsibilities
in assessing what is necessary to communicate to the consumers of our data. Meeting the
guidelines involved the development of multiple databases, bespoke software packages, and an
ontology. Applying the ARRIVE guidelines has proven to be a challenge, but the resulting
transparency has encouraged good practice and allows IMPC phenotype data to be fairly evalu-
ated. The effort has been worthwhile and the value, both internally and externally, is clear.
However, it also highlights the scale of effort needed for the general biological community to
improve reporting of in vivo experiments.
Materials and Methods
For the example presented in S1 Fig, looking at the impact of the Nptn gene knockout on the
lean mass phenotype, mice carrying the Nptn tm1b(EUCOMM)Hmgu targeted allele were created by
blastocyst injection of targeted ES cells, and bred on the C57BL/6NTac genetic background (ac-
cession number: MGI:5548382). Phenotyping data was collected on nine female and eight male
homozygous mice and 1,079 female and 1,107 male baseline control mice collected during
the project.
Ethics Statement
The care and use of all mice in the Nptn study were carried out in accordance with United
Kingdom Home Office regulations and the Animals (Scientific Procedures) Act of 1986
Amendment Regulations 2012 (SI 4 2012/3039). This study has been approved by the Animal
Welfare and Ethical Review Board (AWERB), resulting in the licence 30/2890. All efforts were
made to minimize suffering by considerate housing and husbandry, the details of which are
available at the IMPC portal: http://www.mousephenotype.org/about-impc/arrive-guidelines.
Animal welfare was assessed routinely for all mice involved. Adult mice were killed by ter-
minal anaesthesia followed by exsanguination, and death was confirmed by either cervical dis-
location or cessation of circulation.
Dual-Energy X-ray Absorptiometry (DEXA)
At 14 weeks of age, the DEXA procedure was followed as detailed in the standardised protocol
specified at https://www.mousephenotype.org/impress/protocol/90/7 using a Lunar Piximus II
Bone Densitometer (GE Medical Systems, UK) after the animals were anaesthetized with iso-
flurane (2% Abbott Animal Health, US). The details of blinding and randomisation methods
implemented are described at http://www.mousephenotype.org/about-impc/arrive-guidelines.
Supporting Information
S1 Fig. Organising the information for rapid user access. Organising the information in a
web user interface is challenging. Shown are screen shots from a genotype-phenotype page to
highlight how the information is organised and presented. A: An example visualisation of
phenotyping data. B: An example presentation of associated statistical output. The example
shown is the lean mass output from the Dual Energy X-ray Absorptiometry screen for the
Nptntm1b(EUCOMM)Hmgu knockout line (accession number: MGI:5548382).
(TIFF)
S2 Fig. Classification of the observed genotype effect. As the majority of the phenotyping
data are collected on both sexes, this has enabled the regression methods to include an assess-
ment of sexual dimorphism. The output of the model fitting can then be used to classify the ge-
notype effect observed in relationship to the sex of the animals. For example, whether the
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genotype effect was observed in both sexes equally will lead to the tag “both sexes equally” or
specifically to one sex (e.g., “males only”). Occasionally the model optimisation procedure im-
plemented will find that there was statistical evidence of sexual dimorphism but when it came
to identifying how this occurred and quantifying the effect for each sex, there is insufficient
power. In this scenario, the classification returned states that it “cannot classify the effect.”
(PDF)
S1 Table. The various instrument bias management options available to describe how insti-
tutes manage potential instrument effects. The table lists the various ontologies and associat-
ed definitions that were developed to describe the strategies used in the implementation of the
phenotyping experiments to manage the potential effect of instrument bias.
(PDF)
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